Vinorelbine in Mesothelioma

PHASE2CompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

March 1, 2016

Primary Completion Date

March 17, 2021

Study Completion Date

March 17, 2021

Conditions
Mesothelioma
Interventions
DRUG

Vinorelbine

Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.

OTHER

Active Symptom Control

Trial Locations (1)

CF14 4YS

Wales Cancer Trials Unit, Cardiff

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Pierre Fabre Laboratories

INDUSTRY

lead

Wales Cancer Trials Unit

OTHER